Ultragenyx Pharmaceutical (RARE) News Today → Gold Mania (From Stansberry Research) (Ad) Free RARE Stock Alerts $42.75 -0.45 (-1.04%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Analystsamericanbankingnews.com - May 4 at 4:06 AMTruist Financial Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)markets.businessinsider.com - May 4 at 3:22 AMAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)markets.businessinsider.com - May 3 at 10:22 PMWedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)markets.businessinsider.com - May 3 at 10:22 PMUltragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...finance.yahoo.com - May 3 at 10:22 PMUltragenyx Pharmaceutical (NASDAQ:RARE) Releases Quarterly Earnings Results, Misses Estimates By $0.31 EPSmarketbeat.com - May 3 at 8:51 PMCantor Fitzgerald Reiterates "Overweight" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)marketbeat.com - May 3 at 12:17 PMWedbush Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $47.00marketbeat.com - May 3 at 11:13 AMUltragenyx: Q1 Earnings Snapshotsfgate.com - May 2 at 10:11 PMUltragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $108.8M misses by $7.64Mmsn.com - May 2 at 10:11 PMRARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024investorplace.com - May 2 at 10:05 PMUltragenyx Reports First Quarter 2024 Financial Results and Corporate Updateglobenewswire.com - May 2 at 4:00 PMUltragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Diseaseglobenewswire.com - April 30 at 4:00 PMUltragenyx Pharmaceutical: Strong Buy Rating on Growth Prospects and Pipeline Potentialmarkets.businessinsider.com - April 30 at 12:29 PMUltragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)finance.yahoo.com - April 30 at 12:29 PM141,117 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by abrdn plcmarketbeat.com - April 27 at 5:25 AMUltragenyx Pharmaceutical (RARE) to Release Quarterly Earnings on Thursdaymarketbeat.com - April 26 at 11:02 AMTD Cowen Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $61.00americanbankingnews.com - April 26 at 4:44 AMUltragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Updateglobenewswire.com - April 25 at 4:30 PMFirst Week of RARE June 21st Options Tradingnasdaq.com - April 24 at 9:26 PMUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $61.00 at TD Cowenmarketbeat.com - April 24 at 1:57 PMAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)markets.businessinsider.com - April 23 at 12:46 PMForecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceuticalmarkets.businessinsider.com - April 22 at 9:44 AMUltragenyx Pharmaceutical (NASDAQ:RARE) Receives New Coverage from Analysts at Royal Bank of Canadamarketbeat.com - April 22 at 8:29 AMUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 19 at 4:30 PMUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Raised by Federated Hermes Inc.marketbeat.com - April 18 at 12:23 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)markets.businessinsider.com - April 18 at 9:38 AMUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 1.9%marketbeat.com - April 16 at 1:40 PMWedbush Reiterates Neutral Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)marketbeat.com - April 16 at 11:00 AMMirae Asset Global Investments Co. Ltd. Has $5.18 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)marketbeat.com - April 16 at 5:04 AMWhy Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionmsn.com - April 15 at 6:23 PMUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down to $47.00marketbeat.com - April 15 at 12:53 PMUltragenyx Reports Positive Interim Phase 1/2 Data With GTX-102 - Quick Factsmarkets.businessinsider.com - April 15 at 8:22 AMUltragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102finance.yahoo.com - April 15 at 8:22 AMUltragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndromeglobenewswire.com - April 12 at 4:22 PMUltragenyx Pharmaceutical Inc.: Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meetingfinanznachrichten.de - April 12 at 9:58 AMUltragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meetingglobenewswire.com - April 12 at 8:00 AMUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Lessened by Peregrine Capital Management LLCmarketbeat.com - April 11 at 7:49 AMUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analystsmarketbeat.com - April 9 at 4:41 AMUltragenyx Pharmaceutical, Inc.cnn.com - April 7 at 3:58 AMExpert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analystsmarkets.businessinsider.com - April 5 at 4:16 PMUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 5.7%marketbeat.com - April 5 at 2:38 PMUltragenyx Pharmaceutical (NASDAQ:RARE) Receives "Overweight" Rating from Cantor Fitzgeraldmarketbeat.com - April 5 at 10:27 AMAssenagon Asset Management S.A. Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)marketbeat.com - March 31 at 4:42 AMVanguard Group Inc. Purchases 214,666 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)marketbeat.com - March 30 at 4:09 AMUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - March 22 at 4:00 PMUltragenyx Pharmaceutical Inc.money.usnews.com - March 22 at 8:45 AMUltragenyx Pharmaceutical (NASDAQ:RARE) PT Raised to $92.00marketbeat.com - March 18 at 2:52 PMAnalyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceuticalmarkets.businessinsider.com - March 18 at 12:58 PMUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Deutsche Bank AGmarketbeat.com - March 18 at 4:43 AM Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent Nvidia Warning (Ad)Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space. Click here to access… RARE Media Mentions By Week RARE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼-0.150.43▲Average Medical News Sentiment RARE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼185▲RARE Articles Average Week Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Crinetics Pharmaceuticals News Prestige Consumer Healthcare News Biohaven News Insmed News CymaBay Therapeutics News HUTCHMED News Bausch Health Companies News Xenon Pharmaceuticals News IDEAYA Biosciences News Amicus Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
